21ьз╕ C

Lilly announces plans to build $5 billion manufacturing facility in Virginia

News Provided by PR Newswire2025-09-16

Lilly announces plans to build $5 billion manufacturing facility in Virginia

[16-September-2025]

New site in Virginia's Goochland County will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune and other advanced therapies

Company will create 2,450 high-wage manufacturing and construction jobs

This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year

INDIANAPOLIS, Sept. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The new site will be the company's first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio.

Earlier this year, at a press conference in Washington, D.C., Lilly announced plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. The planned Virginia facility is the first to be announced and is part of the company's $50 billion in U.S. capital expansion commitments since 2020. At this site, Lilly will also boost its domestic manufacturing of antibody-drug conjugates (ADCs).

An ADC is a targeted therapy designed to deliver potent medicines directly to diseased cells. By combining the precision of monoclonal antibodies with the power of cytotoxic medicines, ADCs can act like highly specialized carriers, maximizing treatment effectiveness while reducing harm to healthy tissue. They are primarily used to treat cancer but are being explored for autoimmune diseases and other conditions.

"Our investment in Virginia underscores our commitment to U.S. innovation and manufacturing – creating high-quality jobs, strengthening communities and advancing the health and well-being of Americans nationwide," said David A. Ricks, Lilly chair and CEO. "By expanding our domestic capacity, we're building a secure, resilient supply chain that delivers for patients today and supports the breakthrough medicines of tomorrow."

Expected to be completed within the next five years, the manufacturing site will bring more than 650 new high-paying jobs to Virginia, including highly skilled engineers, scientists, operations personnel and lab technicians. The project is anticipated to bring 1,800 construction jobs to the region and greatly benefit the local economy.

Lilly's capital investment and jobs numbers announced today go beyond what the company initially committed to in the Virginia incentive process submission, reinforcing the importance this new site will have in the company's ability to deliver medicines to people in the U.S. and around the world. The company expects that for every dollar invested in the Virginia facility, up to four dollars will be generated in local economic activity. Additionally, each manufacturing job will support multiple positions in related industries like supply chain, logistics and retail.

"Lilly is one of the world's great innovators, and I want to thank them for this significant commitment to Virginia," said Governor Glenn Youngkin. "This new facility in Goochland County will create 650 great jobs, along with 1,800 construction jobs, and deliver some of the most advanced medicines in Lilly's portfolio, powered by the unmatched talent of our Virginia workforce. By expanding manufacturing capacity here in the United States, we are strengthening our economy, securing America's critical pharmaceutical supply chain, and positioning Virginia to lead in the industries that will drive innovation for generations to come." 

Lilly will use advanced technologies such as machine learning, AI and automated systems at the site. This will enable right-first-time execution, all in support of the safe and reliable supply of medicines. To maximize the latest technology, digital integrations and automation, the company plans to engage locally, partnering with local universities and supporting community educational initiatives in Virginia.

"This isn't just another manufacturing site — it represents a significant milestone for Lilly, as we begin building our first bioconjugate facility," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "With this cutting-edge site, Lilly is setting a new benchmark in bioconjugate innovation, advancing technologies that will expand what's possible for patients. This investment reflects our bold vision, our commitment to transformative technologies and our dedication to being a good neighbor through sustainability efforts and support of local education and community partnerships."

Goochland County was selected from hundreds of applications based on several criteria, including, but not limited to, workforce potential in the Greater Richmond Region, local incentives, ready access to utilities and transportation and favorable zoning. Lilly champions a culture of safety and environmental stewardship at its numerous manufacturing sites, embracing innovative technologies to significantly minimize the company's environmental footprint.

The company plans to announce the three remaining U.S. manufacturing sites this year and expects to begin making medicines at these four facilities within five years.

Support for Lilly's job creation will be provided, in part, through the Virginia Talent Accelerator Program. The program was created by the Virginia Economic Development Partnership in collaboration with higher education partners.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) including about planned capital investments in new manufacturing capacity, certain medical treatments, economic impact of investment, production of medicines, hiring and related initiatives and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the manufacturing process, development and commercialization of pharmaceutical products any of which could impact the overall commercial success of our products, and as related to cost, completion timing, expected capacity, personnel, and other factors which could impact expected benefits of the capacity expansion and related initiatives. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Refer to: Carla Cox; cox_carla@lilly.com; 317-750-3923 (Media)
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)